Calix, Inc CALX
6 trading plans running, 4 Form 144 notices for $7.3M
10-Q, 10-K and Form 144What CALX's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Feb 7, 2025 to Nov 25, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Shane Eleniak Chief Product Officer |
Adopted 10b5-1 plan | Jul 28, 2026 | 10-Q Nov 3, 2026 | ||
What the company wroteOn July 28, 2026, Shane Eleniak, Chief Product Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Rule 10b5-1 trading arrangement allows for the sale of up to 364,000 shares of Common Stock, at market prices, commencing November 2026, and continuing until April 30, 2027. | |||||
| Carl Russo Chairman of the Board of Directors |
Adopted 10b5-1 plan | Apr 23, 2026 | 10-Q Jul 21, 2026 | ||
What the company wroteCarl Russo, Chairman of the Board of Directors of the Company, is Trustee of The Crescentico Trust U/A DTD 09/06/1999. On April 23, 2026, The Crescentico Trust adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Rule 10b5-1 trading arrangement allows for the sale of up to 300,000 shares of Common Stock, at market prices, commencing July 2026, and continuing until May 28, 2027. | |||||
| Michael Weening Director, President and Chief Executive Officer |
Adopted 10b5-1 plan | Feb 19, 2026 | 10-Q Apr 22, 2026 | ||
What the company wroteOn February 19, 2026, Michael Weening, Director, President and Chief Executive Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Weening 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Weening 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 397,100 shares of Common Stock, at specific market prices, commencing on May 21, 2026, and continuing until all such options are exercised and the underlying shares are sold, or February 19, 2027, whichever comes first. | |||||
| Cory Sindelar Chief Financial Officer |
Adopted 10b5-1 plan | Feb 17, 2026 | 10-Q Apr 22, 2026 | ||
What the company wroteOn February 17, 2026, Cory Sindelar, Chief Financial Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Sindelar 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Sindelar 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 256,000 shares of Common Stock, at specific market prices, commencing on July 1, 2026, and continuing until all such options are exercised and the underlying shares are sold, or May 31, 2027, whichever comes first. | |||||
| Shane Eleniak Chief Product Officer |
Adopted 10b5-1 plan | Feb 17, 2026 | 10-Q Apr 22, 2026 | ||
What the company wroteOn February 17, 2026, Shane Eleniak, Chief Product Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Eleniak 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Eleniak 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 364,000 shares of Common Stock, at specific market prices, commencing on May 19, 2026, and continuing until all such options are exercised and the underlying shares are sold, or October 30, 2026, whichever comes first. | |||||
| Kevin Peters Lead Independent Director of the Board of Directors |
Adopted 10b5-1 plan | Nov 26, 2025 | 10-K Feb 20, 2026 | ||
What the company wroteOn November 26, 2025, Kevin Peters, Lead Independent Director of the Board of Directors of the Company, adopted a Rule 10b5-1 trading arrangement (the “Peters 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Peters 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 39,478 shares of Common Stock, at specific market prices, commencing on or about February 25, 2026, and continuing until all such options are exercised and the underlying shares are sold, or November 25, 2027, whichever comes first. | |||||
| John Durocher Chief Operating Officer |
Adopted 10b5-1 plan | Nov 25, 2025 | 10-K Feb 20, 2026 | ||
What the company wroteOn November 25, 2025, John Durocher, Chief Operating Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Durocher 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Durocher 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 216,370 shares of Common Stock, at specific market prices, commencing on or about February 25, 2026, and continuing until all such options are exercised and the underlying shares are sold, or November 25, 2026, whichever comes first. | |||||
| Michael Weening Director, President and Chief Executive Officer |
Adopted 10b5-1 plan | Feb 28, 2025 | 10-Q Apr 22, 2025 | ||
What the company wroteOn February 28, 2025, Michael Weening, Director, President and Chief Executive Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Weening 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Weening 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 974,000 shares of Common Stock, at specific market prices, commencing on May 30, 2025, and continuing until all such options are exercised and the underlying shares are sold, or February 28, 2026, whichever comes first. | |||||
| Cory Sindelar Chief Financial Officer |
Adopted 10b5-1 plan | Feb 7, 2025 | 10-Q Apr 22, 2025 | ||
What the company wroteOn February 7, 2025, Cory Sindelar, Chief Financial Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Sindelar 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Sindelar 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 130,000 shares of Common Stock, at specific market prices, commencing on May 9, 2025, and continuing until all such options are exercised and the underlying shares are sold, or June 30, 2026, whichever comes first. | |||||
Show the other 1 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since Apr 24, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Nov 6, 2026 | Russo Carl Director, 10% Stockholder |
75,000 | $2.3M |
| Jul 27, 2026 | Russo Carl Officer, Director, 10% Stockholder |
75,000 | $2.7M |
| Apr 27, 2026 | Russo Carl Officer, Director, 10% Stockholder |
25,000 | $1.1M |
| Feb 3, 2026 | Russo Carl Officer, Director, 10% Stockholder |
25,000 | $1.2M |
From the Form 144 XML filed with the SEC, since Feb 3, 2026. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CALX/export.csv") into a cell.